| 27/04/23 | 17:30:01 | 27 Apr 2023 | | Result of AGM | RNS |
| 27/04/23 | 07:05:01 | 27 Apr 2023 | | Board Committee Changes | RNS |
| 27/04/23 | 07:00:05 | 27 Apr 2023 | | 1st Quarter Results | RNS |
| 26/04/23 | 16:45:01 | 26 Apr 2023 | | Director Declaration | RNS |
| 11/04/23 | 07:00:08 | 11 Apr 2023 | | Update to arrangements with Sobi and Sanofi | RNS |
| 05/04/23 | 07:00:04 | 5 Apr 2023 | | Lynparza + Imfinzi met endpoint in ovarian cancer | RNS |
| 03/04/23 | 15:00:01 | 3 Apr 2023 | | Total Voting Rights | RNS |
| 03/04/23 | 07:00:11 | 3 Apr 2023 | | Ultomiris recommended for NMOSD EU approval | RNS |
| 30/03/23 | 07:00:03 | 30 Mar 2023 | | AstraZeneca completes KYM agreement for CMG901 | RNS |
| 27/03/23 | 11:00:01 | 27 Mar 2023 | | Director/PDMR Shareholding | RNS |
| 22/03/23 | 11:00:02 | 22 Mar 2023 | | Notice of AGM | RNS |
| 09/03/23 | 07:00:06 | 9 Mar 2023 | | Imfinzi improved EFS in resectable lung cancer | RNS |
| 08/03/23 | 11:01:01 | 8 Mar 2023 | | Director/PDMR Shareholding | RNS |
| 08/03/23 | 11:00:01 | 8 Mar 2023 | | Director/PDMR Shareholding | RNS |
| 06/03/23 | 07:00:04 | 6 Mar 2023 | | Enhertu DESTINY-PanTumor02 shows positive results | RNS |
| 01/03/23 | 15:00:01 | 1 Mar 2023 | | Total Voting Rights | RNS |
| 01/03/23 | 07:00:10 | 1 Mar 2023 | | AstraZeneca prices a $2.25bn bond offering | RNS |
| 24/02/23 | 18:15:00 | 24 Feb 2023 | | AstraZeneca prices a EUR1.5bn bond offering | RNS |
| 24/02/23 | 14:05:01 | 24 Feb 2023 | | AstraZeneca acquires CinCor for cardiorenal asset | RNS |
| 24/02/23 | 11:00:01 | 24 Feb 2023 | | Director/PDMR Shareholding | RNS |
| 23/02/23 | 07:00:08 | 23 Feb 2023 | | AstraZeneca enters agreement with KYM for CMG901 | RNS |
| 22/02/23 | 07:10:02 | 22 Feb 2023 | | Filing of Form 20-F with SEC | RNS |
| 21/02/23 | 11:00:01 | 21 Feb 2023 | | Annual Financial Report | RNS |
| 13/02/23 | 14:01:01 | 13 Feb 2023 | | Director/PDMR Shareholding | RNS |
| 13/02/23 | 14:00:01 | 13 Feb 2023 | | Director/PDMR Shareholding | RNS |
| 09/02/23 | 07:00:08 | 9 Feb 2023 | | Final Results | RNS |
| 01/02/23 | 15:00:00 | 1 Feb 2023 | | Total Voting Rights | RNS |
| 26/01/23 | 18:15:00 | 26 Jan 2023 | | Update on Evusheld US EUA | RNS |
| 16/01/23 | 07:00:05 | 16 Jan 2023 | | Acquisition of Neogene Therapeutics completed | RNS |
| 11/01/23 | 13:00:01 | 11 Jan 2023 | | Airsupra (PT027) approved in US for asthma | RNS |
| 09/01/23 | 07:00:02 | 9 Jan 2023 | | AstraZeneca acquire CinCor for cardiorenal asset | RNS |
| 03/01/23 | 15:00:01 | 3 Jan 2023 | | Total Voting Rights | RNS |
| 30/12/22 | 11:00:01 | 30 Dec 2022 | | Director/PDMR Shareholding | RNS |
| 28/12/22 | 07:05:06 | 28 Dec 2022 | | Calquence Japan approval for treatment-naïve CLL | RNS |
| 28/12/22 | 07:00:08 | 28 Dec 2022 | | Imfinzi, Imjudo approved in Japan for 3 cancers | RNS |
| 21/12/22 | 07:05:00 | 21 Dec 2022 | | Lynparza approved in EU for prostate cancer | RNS |
| 21/12/22 | 07:00:05 | 21 Dec 2022 | | Imfinzi approved in EU for biliary tract cancer | RNS |
| 19/12/22 | 07:20:03 | 19 Dec 2022 | | Enhertu recommended for EU approval in HER2-low BC | RNS |
| 19/12/22 | 07:15:04 | 19 Dec 2022 | | Enhertu approved in EU for gastric cancer | RNS |
| 19/12/22 | 07:10:04 | 19 Dec 2022 | | Imfinzi + Imjudo recommended for approvals in EU | RNS |
| 19/12/22 | 07:05:03 | 19 Dec 2022 | | Update on Imfinzi PEARL trial | RNS |
| 19/12/22 | 07:00:06 | 19 Dec 2022 | | Forxiga CHMP opinion for symptomatic chronic HF | RNS |
| 15/12/22 | 07:00:02 | 15 Dec 2022 | | Update on US review of Lynparza PROpel sNDA | RNS |
| 08/12/22 | 13:30:01 | 8 Dec 2022 | | Capivasertib PFS in HR-positive breast cancer | RNS |
| 01/12/22 | 15:00:04 | 1 Dec 2022 | | Block listing Interim Review | RNS |
| 01/12/22 | 15:00:04 | 1 Dec 2022 | | Total Voting Rights | RNS |
| 30/11/22 | 07:05:01 | 30 Nov 2022 | | AstraZeneca announces sale of West Chester site | RNS |
| 29/11/22 | 07:00:06 | 29 Nov 2022 | | AstraZeneca to acquire Neogene Therapeutics | RNS |
| 23/11/22 | 15:30:01 | 23 Nov 2022 | | Director/PDMR Shareholding | RNS |
| 14/11/22 | 07:10:05 | 14 Nov 2022 | | Enhertu recommended for EU approval in gastric | RNS |
